rufinamide
E939682
Rufinamide is an anticonvulsant medication primarily used to help control seizures in patients with Lennox-Gastaut syndrome.
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
anticonvulsant drug
ⓘ
antiepileptic drug ⓘ pharmaceutical compound ⓘ |
| hasATCCode | N03AF03 ⓘ |
| hasBioavailability | increased with food ⓘ |
| hasBrandName |
Banzel
NERFINISHED
ⓘ
Inovelon NERFINISHED ⓘ |
| hasCASNumber | 106308-44-5 ⓘ |
| hasChemicalFormula | C10H8F2N4O ⓘ |
| hasCommonAdverseEffect |
dizziness
ⓘ
fatigue ⓘ headache ⓘ loss of appetite ⓘ nausea ⓘ somnolence ⓘ vomiting ⓘ |
| hasContraindication | familial short QT syndrome ⓘ |
| hasDeveloper | Eisai Co., Ltd. NERFINISHED ⓘ |
| hasDrugInteraction |
CYP3A4 inducers
ⓘ
oral contraceptives ⓘ valproic acid ⓘ |
| hasEffect | reduction of seizure frequency ⓘ |
| hasEliminationHalfLife | approximately 6 to 10 hours ⓘ |
| hasFDAApprovalYear | 2008 ⓘ |
| hasIUPACName | 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide ⓘ |
| hasMechanismOfAction |
modulation of voltage-gated sodium channels
ⓘ
prolongation of the inactive state of sodium channels ⓘ |
| hasMolarMass | 238.19 g/mol ⓘ |
| hasPregnancyCategory | Category C (US, historical) ⓘ |
| hasPrimaryMetabolismSite | liver ⓘ |
| hasProteinBinding | approximately 34 percent ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
multiorgan hypersensitivity reactions
ⓘ
status epilepticus ⓘ suicidal ideation ⓘ |
| hasTargetPopulation |
adult patients with Lennox-Gastaut syndrome
ⓘ
patients with Lennox-Gastaut syndrome ⓘ pediatric patients with Lennox-Gastaut syndrome ⓘ |
| hasWarning |
risk of QT interval shortening
ⓘ
risk of suicidal behavior and ideation ⓘ |
| isAdministeredAs |
oral suspension
ⓘ
oral tablet ⓘ |
| isExcretedVia | kidney ⓘ |
| isIndicatedFor |
Lennox-Gastaut syndrome
NERFINISHED
ⓘ
adjunctive treatment of seizures ⓘ |
| isMetabolizedBy | carboxylesterases ⓘ |
| isPrescriptionOnly | true ⓘ |
| isTakenWithFood | recommended ⓘ |
| isUsedFor | treatment of seizures associated with Lennox-Gastaut syndrome ⓘ |
| wasApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.